Metanephrines (Neuroblastoma)
Recruiting
Who can enter
Children with newly diagnosed high-risk neuroblastoma who are being treated according to the SIOPEN HR-NBL-2 protocol
Age: 1-18 years
Goal
The goal of this study is to investigate the role of specific metabolites that are released in the blood in children with high-risk neuroblastoma.
Background
Background
Neuroblastoma cells can secrete specific metabolites that end up in the urine and blood of neuroblastoma patients. These distinct metabolites can be used to help diagnose neuroblastoma patients. Until now, we always measure the metabolites in urine. Now we want to investigate whether it is more accurate to measure these specific metabolites in blood.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
Last reviewed
March 23, 2026
Study details
- Study details
Official title
International multicenter observational study to determine the diagnostic sensitivity of plasma metanephrines and urinary catecholamines and metabolites compared to standard evaluation procedures in children with high risk neuroblastomaCancer type
NeuroblastomaMaximum number of patients
130, of whom 30 are expected to participate in the NetherlandsStart date
July 15, 2022Status
Open for inclusionLocal principal investigator
Dr. G.A.M. TytgatSponsor
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
Registry CCMO: NL80132.041.22
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.